Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder
January 31, 2023 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Jan. 31, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
January 11, 2023 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Resolves Neuronetics Litigation
January 10, 2023 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for...
BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom
December 13, 2022 09:15 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for...
BrainsWay Reports Open Market Stock Purchases by Two Board Members
November 28, 2022 07:30 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for...
BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights
November 16, 2022 07:30 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 16, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for...
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™
November 03, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay to Report Third Quarter Financial Results on November 16, 2022
November 02, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
November 01, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Nov. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month
October 12, 2022 08:00 ET
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of...